guest ::
| Home > Publications database > Performance and feasibility of self-microsampling of capillary blood and saliva for serological testing of SARS-CoV-2. > print |
| Home > Publications database > Performance and feasibility of self-microsampling of capillary blood and saliva for serological testing of SARS-CoV-2. > print |
| 001 | 303011 | ||
| 005 | 20250727021618.0 | ||
| 024 | 7 | _ | |a 10.1371/journal.pone.0327821 |2 doi |
| 024 | 7 | _ | |a pmid:40644438 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12250565 |2 pmc |
| 024 | 7 | _ | |a altmetric:179287351 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01458 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Morales, Ivonne |0 0000-0001-6803-9284 |b 0 |
| 245 | _ | _ | |a Performance and feasibility of self-microsampling of capillary blood and saliva for serological testing of SARS-CoV-2. |
| 260 | _ | _ | |a San Francisco, California, US |c 2025 |b PLOS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1753095451_5172 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Serology is a valuable tool to estimate infections, case-fatality rates, and immunity. However, venipuncture and clinical infrastructure hinder scalability. This study evaluated the performance, feasibility and user experience of using a microsampling device for self-collected capillary blood and saliva to determine total SARS-CoV-2 S RBD antibodies.It included 149 participants with (n = 48) or without (n = 101) a known history of SARS-CoV-2 infection and confirmed antibodies. Venous and capillary blood were self- or professionally collected from all, and saliva was self-collected by 46/48 participants with antibodies. The detection of SARS-CoV-2 S RBD antibodies in all sample types was tested using a high-throughput platform and agreement was calculated. Intra- and inter-rater agreement between serum and capillary blood in participants with an unknown antibody status was also assessed. Participants evaluated the device's user-friendliness through questionnaires.Among the 48 participants with known past infection and antibodies, agreement was 100% (95% CI: 92.6-100) between serum and capillary blood (self-collected or professionally collected). Self-collected saliva had slightly lower agreement with paired serum samples (95.7%, CI: 85.2-99.5). For the 101 participants without prior evidence of antibodies or infection, serum and self-collected capillary blood had good intra-rater agreement and serum and professionally collected capillary blood had almost perfect intra-rater agreement. Inter-rater agreement was also almost perfect. While 81.8% found the self-finger prick easy, 53.4% found using the microsampler easy. Among those who collected saliva, 84.8% found capillary blood easier to collect compared to saliva (52.2%).Our results show that detecting SARS-CoV-2 antibodies from capillary blood and saliva collected with the VAMS microsampling device is feasible and yields valid results. To ensure accuracy and reliability, additional training in self-sampling techniques may be essential. The positive user experience further underscores the microsampling device's potential for scalable serosurveillance and strengthening pandemic preparedness efforts. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Antibodies, Viral |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Saliva: virology |2 MeSH |
| 650 | _ | 2 | |a COVID-19: diagnosis |2 MeSH |
| 650 | _ | 2 | |a COVID-19: blood |2 MeSH |
| 650 | _ | 2 | |a COVID-19: virology |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a SARS-CoV-2: immunology |2 MeSH |
| 650 | _ | 2 | |a SARS-CoV-2: isolation & purification |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Antibodies, Viral: blood |2 MeSH |
| 650 | _ | 2 | |a Antibodies, Viral: analysis |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Feasibility Studies |2 MeSH |
| 650 | _ | 2 | |a COVID-19 Serological Testing: methods |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Specimen Handling: methods |2 MeSH |
| 650 | _ | 2 | |a Blood Specimen Collection: methods |2 MeSH |
| 650 | _ | 2 | |a Capillaries |2 MeSH |
| 700 | 1 | _ | |a Bueggeln, Josh |b 1 |
| 700 | 1 | _ | |a Denzler, Anna |b 2 |
| 700 | 1 | _ | |a Sonntag-Buck, Vera |b 3 |
| 700 | 1 | _ | |a Börner, Kathleen |b 4 |
| 700 | 1 | _ | |a Chlanda, Petr |b 5 |
| 700 | 1 | _ | |a Koeppel, Lisa |b 6 |
| 700 | 1 | _ | |a Deckert, Andreas |b 7 |
| 700 | 1 | _ | |a Bärnighausen, Till |b 8 |
| 700 | 1 | _ | |a Knop, Michael |0 P:(DE-He78)03ae15a30a7fa7191475148bf4e7f581 |b 9 |u dkfz |
| 700 | 1 | _ | |a Denkinger, Claudia M |0 0000-0002-7216-7067 |b 10 |
| 773 | _ | _ | |a 10.1371/journal.pone.0327821 |g Vol. 20, no. 7, p. e0327821 - |0 PERI:(DE-600)2267670-3 |n 7 |p e0327821 |t PLOS ONE |v 20 |y 2025 |x 1932-6203 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:303011 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)03ae15a30a7fa7191475148bf4e7f581 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PLOS ONE : 2022 |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-02-08T09:37:46Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-02-08T09:37:46Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2024-02-08T09:37:46Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2024-02-08T09:37:46Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-16 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-16 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-16 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-16 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-16 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-16 |
| 920 | 1 | _ | |0 I:(DE-He78)A260-20160331 |k A260 |l Zellmorphogenese und Signalübermittlung |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A260-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|